Geron's Imetelstat: A Game-Changer in Hematological Cancers
Geron's Imetelstat has emerged as a potential game-changer in the field of hematological cancers. Despite facing competition from other pharmaceutical companies and safety concerns regarding discontinuation rates, this telomerase inhibitor aims to halt the proliferation of malignant hematopoietic stem cells. Geron is the only company …